These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26157327)

  • 1. Single nucleotide polymorphisms of MAGE-A3 gene and its clinical implications in Chinese patients with non-small cell lung cancer (NSCLC).
    Yang XN; Huang L; Chen Y; An SJ; Zhang XC; Liao RQ; Su J; Wu YL
    Chin J Cancer Res; 2015 Jun; 27(3):301-8. PubMed ID: 26157327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non-small cell lung cancer patients.
    Pan SH; Su KY; Spiessens B; Kusuma N; Delahaye NF; Gruselle O; Myo A; de Creus A; Louahed J; Chang GC; Yu SL; Yang PC
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e212-e223. PubMed ID: 27519286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of melanoma antigen gene A3 expression in drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced nonsmall cell lung cancer treatment.
    Jin J; Liu BZ; Wu ZM
    J Cancer Res Ther; 2015 Nov; 11 Suppl():C271-4. PubMed ID: 26612451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer.
    Chen X; Wang L; Liu J; Huang L; Yang L; Gao Q; Shi X; Li J; Li F; Zhang Z; Zhao S; Zhang B; Van der Bruggen P; Zhang Y
    Oncol Lett; 2017 Mar; 13(3):1609-1618. PubMed ID: 28454298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers.
    Nomura M; Shigematsu H; Li L; Suzuki M; Takahashi T; Estess P; Siegelman M; Feng Z; Kato H; Marchetti A; Shay JW; Spitz MR; Wistuba II; Minna JD; Gazdar AF
    PLoS Med; 2007 Apr; 4(4):e125. PubMed ID: 17455987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
    Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer.
    Grah JJ; Katalinic D; Juretic A; Santek F; Samarzija M
    Tumori; 2014; 100(1):60-8. PubMed ID: 24675493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of the insulin-like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients.
    Gately K; Forde L; Gray S; Morris D; Corvin A; Tewari P; O'Byrne K
    Mol Clin Oncol; 2015 Sep; 3(5):1073-1079. PubMed ID: 26623053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study.
    Sienel W; Varwerk C; Linder A; Kaiser D; Teschner M; Delire M; Stamatis G; Passlick B
    Eur J Cardiothorac Surg; 2004 Jan; 25(1):131-4. PubMed ID: 14690745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of
    Wu YL; Chien MH; Chou YE; Chang JH; Liu TC; Tsao TC; Chou MC; Yang SF
    J Cancer; 2019; 10(13):2907-2914. PubMed ID: 31281467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in intron 1 of the EGFR gene in non-small cell lung cancer patients.
    Shitara M; Sasaki H; Yokota K; Okuda K; Hikosaka Y; Moriyama S; Yano M; Kawaguchi T; Kubo A; Takada M; Kitahara N; Okumura M; Matsumura A; Iuchi K; Fujii Y
    Exp Ther Med; 2012 Nov; 4(5):785-789. PubMed ID: 23226726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
    Zhang X; Fan J; Li Y; Lin S; Shu P; Ni J; Qin S; Zhang Z
    Tumour Biol; 2016 Jan; 37(1):1061-9. PubMed ID: 26269114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation.
    Yuan P; Huang S; Bao FC; Cao JL; Sheng HX; Shi L; Lv W; Hu J
    Eur J Cancer; 2019 Oct; 120():10-19. PubMed ID: 31446212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
    Nie Q; Yang XN; An SJ; Zhang XC; Yang JJ; Zhong WZ; Liao RQ; Chen ZH; Su J; Xie Z; Wu YL
    Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis.
    Jang SJ; Soria JC; Wang L; Hassan KA; Morice RC; Walsh GL; Hong WK; Mao L
    Cancer Res; 2001 Nov; 61(21):7959-63. PubMed ID: 11691819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib.
    Ma F; Sun T; Shi Y; Yu D; Tan W; Yang M; Wu C; Chu D; Sun Y; Xu B; Lin D
    Lung Cancer; 2009 Oct; 66(1):114-9. PubMed ID: 19201048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The genetic polymorphism of melanoma-associated antigen 1 in Chinese normal donors and hepatoma patients].
    Wang LP; Chen HS; Mei MH; Qin LL; Cong X; Fei R; Xu J; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2004 Mar; 12(3):151-5. PubMed ID: 15059299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of MAGE-A3/6 in primary breast cancer is associated with hormone receptor negative status, high histologic grade, and poor survival.
    Ayyoub M; Scarlata CM; Hamaï A; Pignon P; Valmori D
    J Immunother; 2014; 37(2):73-6. PubMed ID: 24509169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib.
    Winther-Larsen A; Nissen PH; Jakobsen KR; Demuth C; Sorensen BS; Meldgaard P
    Lung Cancer; 2015 Nov; 90(2):314-20. PubMed ID: 26386832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case-Control Study on Impact of the Telomerase Reverse Transcriptase Gene Polymorphism and Additional Single Nucleotide Polymorphism (SNP)- SNP Interaction on Non-Small Cell Lung Cancers Risk in Chinese Han Population.
    Xing YL; Liu F; Li JF; Lin JC; Zhu GD; Li M; Zhang CR; Niu YY
    J Clin Lab Anal; 2016 Nov; 30(6):1071-1077. PubMed ID: 27154632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.